A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy (Q46776289)

25 December 2017

title

A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy (English)

1 reference

25 December 2017

1 reference

7

Roman M Chicz

1 reference

25 December 2017

author name string

Annie Mo

1

1 reference

25 December 2017

Cristina Musselli

2

1 reference

25 December 2017

Hong Chen

3

1 reference

25 December 2017

John Pappas

4

1 reference

25 December 2017

Kenneth Leclair

5

1 reference

25 December 2017

Aston Liu

6

1 reference

25 December 2017

Alemseged Truneh

8

1 reference

25 December 2017

Stephen Monks

9

1 reference

25 December 2017

Daniel L Levey

10

1 reference

25 December 2017

Pramod K Srivastava

11

1 reference

25 December 2017

language of work or name

English

0 references

publication date

19 July 2011

1 reference

25 December 2017

published in

Vaccine

1 reference

25 December 2017

volume

29

1 reference

25 December 2017

issue

47

1 reference

25 December 2017

page(s)

8530-8541

1 reference

25 December 2017

A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

The ‘immunologic advantage’ of HIV-exposed seronegative individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Roles of heat-shock proteins in innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

gp96-peptide vaccination of mice against intracellular bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Natural Killer andNK-LikeT-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Advances in saponin-based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Scant activation of CD8 T cells by antigen loaded on heat shock protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Ligand epitope antigen presentation system vaccines against herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

CD91: a receptor for heat shock protein gp96

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.07.011

1 reference

25 December 2017

1 reference

25 December 2017